Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2012 08:45 ET | Source: DARA BioSciences, Inc.

DARA BioSciences Announces Launch of Bionect for Treatment of Skin Irritation and Burns Associated With Radiation Therapy for Cancer

RALEIGH, N.C., June 6, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA"), an emerging oncology and oncology-support specialty pharmaceutical company, announced...
May 29, 2012 08:45 ET | Source: DARA BioSciences, Inc.

DARA BioSciences Announces New Organizational Responsibilities in Preparation for the Launch of New Products and to Strengthen Product Development Capabilities

RALEIGH, N.C., May 29, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA"), an emerging oncology and oncology-support specialty pharmaceutical company, today...
May 21, 2012 11:04 ET | Source: DARA BioSciences, Inc.

DARA BioSciences Reports Financial Results for the First Quarter 2012 and Provides Key Highlights of the Company's Business Milestones

RALEIGH, N.C., May 21, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA") today announced the financial results for the period ending March 31, 2012. The Company...
May 09, 2012 08:45 ET | Source: DARA BioSciences, Inc.

DARA BioSciences Announces New Analysis of Patient Self-Reported Diary Results in a Phase 2a Clinical Trial of KRN5500 in Patients With Cancer and Neuropathic Pain

External Data Analysis Confirms Earlier Published Drug Efficacy Signal in Patients With Treatment-Refractory Neuropathic Pain DARA to Continue Phase 2 Development Program After Formulation...
May 01, 2012 08:45 ET | Source: DARA BioSciences, Inc.

DARA BioSciences Closes $10.25 Million Public Offering and Regains Compliance With NASDAQ's Stockholders' Equity Requirement

RALEIGH, N.C., May 1, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA") announced that at a closing completed on April 26, 2012, it received $10,250,000 in gross...
April 09, 2012 09:05 ET | Source: DARA BioSciences, Inc.

DARA BioSciences to Raise $10.1 Million in Public Offering

RALEIGH, N.C., April 9, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA") announced that it entered into definitive securities purchase agreements with certain...
March 26, 2012 08:45 ET | Source: DARA BioSciences, Inc.

DARA BioSciences Obtains U.S. Rights to Co-Promote Bionect(R), an FDA Approved Topical Hyaluronic Acid, Exclusively in the Radiation and Oncology Markets

RALEIGH, N.C., March 26, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that it entered into an exclusive agreement with Innocutis Holdings, LLC ("Innocutis") for U.S....
February 15, 2012 08:30 ET | Source: DARA BioSciences, Inc.

DARA BioSciences Signs Exclusive Agreement With Uman Pharma for U.S. Commercialization Rights to Gemcitabine

RALEIGH, N.C., Feb. 15, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that it entered into an exclusive U.S. agreement with Uman Pharma Inc. for commercial rights to...
January 18, 2012 08:45 ET | Source: DARA BioSciences, Inc.

DARA BioSciences Signs Definitive Agreement to Raise $1.7 Million in Registered Direct Offering

RALEIGH, N.C., Jan. 18, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) today announced that it has entered into a definitive agreement with one institutional investor providing for the...
January 17, 2012 08:45 ET | Source: DARA BioSciences, Inc.

DARA BioSciences Announces Acquisition of U.S. Marketing Rights to Soltamox(TM), an FDA Approved Liquid Formulation of Tamoxifen for the Treatment of Breast Cancer

Soltamox™ and Other Product Opportunities Enabled Through Acquisition of Oncogenerix, a Private South Carolina-Based Oncology Company Additional Opportunities to Develop and Distribute...

Next Page keyboard_arrow_right